Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
US FDA grants priority review status ...
Home  »  Community News  »  US FDA grants priori...
US FDA grants priority review status to AbbVie’s sNDA for Viekira Pak without RBV in genotype 1b HCV patients with compensated cirrhosis
Pharma News

AbbVie, a global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) and granted priority review for Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and compensated cirrhosis (Child-Pugh A). The current dosing recommendation for patients with GT1b and compensated cirrhosis is to administer RBV with Viekira Pak for 12 weeks.

The FDA grants priority review designation to investigational therapies that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness.

Viekira Pak is a prescription medicine used with or without ribavirin to treat adults with genotype 1 (GT1) chronic HCV infection, including people who have a certain type of cirrhosis (compensated). Viekira Pak is not for people with advanced cirrhosis (decompensated). If people have cirrhosis, they should talk to a doctor before taking Viekira Pak.

“We are pleased that the FDA has granted priority review for Viekira Pak without ribavirin as a therapy for treating GT1b chronic hepatitis C patients who have compensated cirrhosis,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “The filing of this sNDA further underscores AbbVie’s commitment to patients living with chronic HCV infection.”

The TURQUOISE-III study included in the sNDA evaluated the use of Viekira Pak without RBV for 12 weeks in GT1b patients with compensated cirrhosis (Child-Pugh A). Results demonstrated 100 percent (N=60/60) sustained virologic response at 12 weeks post-treatment (SVR12). No patients discontinued treatment due to adverse events. The most commonly-reported adverse events (=10 percent) were fatigue (22 percent), diarrhea (20 percent), headache (18 percent), arthralgia (10 percent), dizziness (10 percent), insomnia (10 percent) and pruritus (10 percent).

The Centers for Disease Control and Prevention (CDC) estimates that in the United States, 2.7 million people are chronically infected with HCV.2 genotype 1 is the most common HCV in the US. Of the total US population with GT1 HCV infection, approximately 77 percent are genotype 1a (GT1a) and 23 percent are GT1b.

TURQUOISE-III is a multi-center, open-label phase 3b study to evaluate the safety and efficacy of 12 weeks of treatment with Viekira Pak without RBV in adult patients (N=60) with GT1b HCV infection and compensated liver cirrhosis who were treatment-naïve or treatment-experienced (failed previous therapy with pegylated interferon and RBV). The primary endpoint is the rate of sustained virologic response 12 weeks after treatment (SVR12).

Leave a reply

You must be logged in to post a comment.